{
    "root": "5092af6c-29e7-40fe-9e25-46ab5de48bbb",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Nilotinib",
    "value": "20250523",
    "ingredients": [
        {
            "name": "NILOTINIB",
            "code": "F41401512X"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "D&C RED NO. 7",
            "code": "ECW0LZ41X8"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "ALUMINUM OXIDE",
            "code": "LMI26O6933"
        }
    ],
    "indications": "Nilotinib is a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 ) Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy. ( 1.3 )",
    "contraindications": "Recommended Adult Dose: Newly diagnosed Ph+ CML-CP: 300 mg orally twice daily. Resistant or intolerant Ph+ CML-CP and CML-AP: 400 mg orally twice daily. ( 2.1 ) Recommended Pediatric Dose: Newly Diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior TKI therapy: 230 mg/m 2 orally twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg). ( 2.1 ) See Dosage and Administration for full dosing instructions and dose- reduction instructions for toxicity. ( 2.1 ) Reduce starting dose in patients with baseline hepatic impairment. ( 2.7 ) Eligible newly diagnosed adult patients with Ph+ CML-CP who have received nilotinib capsules for a minimum of 3 years and have achieved a sustained molecular response (MR4.5) and patients with Ph+ CML-CP resistant or intolerant to imatinib who have received nilotinib capsules for at least 3 years and have achieved a sustained molecular response (MR4.5) may be considered for treatment discontinuation. ( 2.2 , 2.3 , 5.16 )",
    "warningsAndPrecautions": "Nilotinib capsules, 50 mg are available for oral administration as hard gelatin capsules with yellow opaque body and light orange opaque cap imprinted “APO N50” in black ink. They are supplied as follows:\n                  Bottles of 120                                                                       NDC 60505-3803-7\n                  Nilotinib capsules, 150 mg are available for oral administration as hard gelatin capsules with red opaque body and red opaque cap imprinted “APO N150” in black ink. They are supplied as follows:\n                  \n                     \n                     Outer Carton containing 4 inner cartons (4x28)  NDC 60505-3801-2\n                  Inner Carton of 28 capsules (2x14)  NDC 60505-3801-3Blisters of 28 capsules (2x14) NDC 60505-3801-0\n                  Nilotinib capsules, 200 mg are available for  oral administration as  hard gelatin capsules with yellow opaque body and yellow opaque cap imprinted “APO N200” in maroon ink.   They are supplied as follows:\n                  Outer Carton containing 4 inner cartons (4x28)                   NDC 60505-3802-2\n                  Inner Carton of 28 capsules (2x14) NDC 60505-3802-3  \n                  Blisters of 28 capsules (2x14)                                              NDC 60505-3802-0\n                  Each inner carton contains two blister cards of 14 capsules each, for dosing two in the morning and two in the evening at 12 hour intervals over a 7 day period. \n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Nilotinib capsules are contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome [see Boxed Warning]."
}